BioArctic (BATS-CHIXE:BIOABS) - Stock Price, News & Analysis

BIOABS Stock Overview

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden.

BIOABS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 64.5% below our estimate of its fair value

Earnings are forecast to grow 46.73% per year

Earnings grew by 832.1% over the past year

Risk Analysis

Shares are highly illiquid

BioArctic AB (publ) Competitors

Genus

LSE:GNS

UK£1.2b

NIOX Group

AIM:NIOX

UK£297.6m

Bioventix

AIM:BVXP

UK£225.8m

HUTCHMED (China)

AIM:HCM

UK£2.6b

Price History & Performance

Summary of all time highs, changes and price drops for BioArctic
Historical stock prices
Current Share Price	kr279.80
52 Week High	kr352.60
52 Week Low	kr231.60
Beta	-0.16
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-0.14%
3 Year Change	201.35%
5 Year Change	245.43%
Change since IPO	850.08%

Recent updates

Shareholder Returns

	BIOABS	GB Biotechs	GB Market
7D	0%	5.9%	1.0%
1Y	-0.1%	-26.8%	3.0%

Return vs Industry: BIOABS exceeded the UK Biotechs industry which returned -26.6% over the past year.

Return vs Market: BIOABS matched the UK Market which returned -0.6% over the past year.

Price Volatility

Is BIOABS's price volatile compared to industry and market?
BIOABS volatility
BIOABS Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.8%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.4%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: BIOABS has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BIOABS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	83	Gunilla Osswald	www.bioarctic.se

BioArctic AB (publ) develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. It also develops ABBV-0805, for treating Parkinson’s disease.

BioArctic AB (publ) Fundamentals Summary

How do BioArctic's earnings and revenue compare to its market cap?
BIOABS fundamental statistics
Market cap	kr23.84b
Earnings (TTM)	kr258.61m
Revenue (TTM)	kr610.52m

92.2x

P/E Ratio

39.1x

P/S Ratio

Is BIOABS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIOABS income statement (TTM)
Revenue	kr610.52m
Cost of Revenue	kr75.27m
Gross Profit	kr535.25m
Other Expenses	kr276.64m
Earnings	kr258.61m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 14, 2024

Earnings per share (EPS)	2.93
Gross Margin	87.67%
Net Profit Margin	42.36%
Debt/Equity Ratio	0%

How did BIOABS perform over the long term?

See historical performance and comparison

BIOABS Stock Overview

Rewards

Risk Analysis

BioArctic AB (publ) Competitors

LSE:GNS

UK£1.2b

AIM:NIOX

UK£297.6m

AIM:BVXP

UK£225.8m

AIM:HCM

UK£2.6b

Price History & Performance

Recent News & Updates

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Second quarter 2023 earnings released: kr1.16 loss per share (vs kr0.52 loss in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Recent updates

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Second quarter 2023 earnings released: kr1.16 loss per share (vs kr0.52 loss in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold kr6.5m worth of stock

Insider recently bought kr241k worth of stock

First quarter 2023 earnings released

Independent Director recently sold kr3.3m worth of stock

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)

Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Insufficient new directors

BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board

Insufficient new directors

BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease

Bioarctic AB's (Publ) Partner Eisai Presents Results from lecanemab Confirmatory Phase 3 Clarity Ad Study

BioArctic AB (publ) Expands Portfolio with Alpha-Synuclein Brain Transporter Project

Insufficient new directors

BioArctic develops New treatment for Gaucher's Disease

Third quarter 2022 earnings released

Insufficient new directors

BioArctic AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

BioArctic AB (publ), Annual General Meeting, Jun 01, 2023

Bioarctic Ab's (Publ) Announces Positive Topline Results for the Large Global Phase 3 Confirmatory Clarity Ad Study in 1,795 Subjects

Insufficient new directors

Bioarctic AB (Publ) Announces Latest Data on Lecanemab Presented At Alzheimer's Association International Conference (Aaic)

Full year 2021 earnings released: kr1.36 loss per share (vs kr0.78 loss in FY 2020)

Bioarctic AB Announces Executive Changes

BioArctic AB (publ) to Report Fiscal Year 2021 Final Results on Mar 31, 2022

DIAN-TU Enrolls First Subject for the Tau Nexgen Study with Lecanemab as Back-Ground Anti-Amyloid Treatment

Bioarctic AB (Publ) Announces Lecanemab Granted Fast Track Designation by the FDA

Insufficient new directors

BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Alzheimer's Disease

Independent Director has left the company

Shareholder Returns

Price Volatility

About the Company

BioArctic AB (publ) Fundamentals Summary

92.2x

39.1x

Earnings & Revenue